Effect of exogenous growth hormone on glucose utilization in burn patients

Dennis Gore, Darcy Honeycutt, Farook Jahoor, Tom Rutan, Robert R. Wolfe, David Herndon

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The treatment of burn patients with recombinantly derived human growth hormone (rHGH) appears effective in counteracting protein catabolism. However, exogenous growth hormone is frequently associated with hyperglycemia, an aspect which may limit its usefulness. Therefore, to assess the affect of rHGH on glucose utilization, 13 severely burned patients (65% ± 4 TBSA burn; mean ± SEM) began receiving on admission either placebo or rHGH (0.2 mg/kg.d) in a double-blind randomized fashion. While hypermetabolic (percentage REE/predicted REE 1.41 ± 0.11) fasting oxygen consumption and CO2 production were measured using indirect calorimetry prior to and then during a hyperinsulinemic euglycemic clamp. This experiment demonstrated that rHGH significantly reduced glucose uptake and inhibited glucose oxidation compared to the placebo patients. Since the decreases in glucose oxidation and uptake were proportional, glucose utilization (percentage glucose uptake oxidized) remained similar in both patient groups. Furthermore, the hyperinsulinemic clamp lowered the plasma amino acid concentrations in the control patients while rHGH-treated patients had no significant alterations. In conclusion, exogenous growth hormone therapy induces an insulin resistance in burn patients. Furthermore, since the glucose utilization did not change, it is likely that the mechanism of insulin resistance is due to a deficiency in glucose transport.

Original languageEnglish (US)
Pages (from-to)518-523
Number of pages6
JournalJournal of Surgical Research
Volume51
Issue number6
DOIs
StatePublished - 1991

Fingerprint

Growth Hormone
Human Growth Hormone
Glucose
Insulin Resistance
Placebos
Indirect Calorimetry
Glucose Clamp Technique
Oxygen Consumption
Hyperglycemia
Fasting
Amino Acids
Therapeutics
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Effect of exogenous growth hormone on glucose utilization in burn patients. / Gore, Dennis; Honeycutt, Darcy; Jahoor, Farook; Rutan, Tom; Wolfe, Robert R.; Herndon, David.

In: Journal of Surgical Research, Vol. 51, No. 6, 1991, p. 518-523.

Research output: Contribution to journalArticle

Gore, Dennis ; Honeycutt, Darcy ; Jahoor, Farook ; Rutan, Tom ; Wolfe, Robert R. ; Herndon, David. / Effect of exogenous growth hormone on glucose utilization in burn patients. In: Journal of Surgical Research. 1991 ; Vol. 51, No. 6. pp. 518-523.
@article{f87e78aabdaf4dbe9734efae91578769,
title = "Effect of exogenous growth hormone on glucose utilization in burn patients",
abstract = "The treatment of burn patients with recombinantly derived human growth hormone (rHGH) appears effective in counteracting protein catabolism. However, exogenous growth hormone is frequently associated with hyperglycemia, an aspect which may limit its usefulness. Therefore, to assess the affect of rHGH on glucose utilization, 13 severely burned patients (65{\%} ± 4 TBSA burn; mean ± SEM) began receiving on admission either placebo or rHGH (0.2 mg/kg.d) in a double-blind randomized fashion. While hypermetabolic (percentage REE/predicted REE 1.41 ± 0.11) fasting oxygen consumption and CO2 production were measured using indirect calorimetry prior to and then during a hyperinsulinemic euglycemic clamp. This experiment demonstrated that rHGH significantly reduced glucose uptake and inhibited glucose oxidation compared to the placebo patients. Since the decreases in glucose oxidation and uptake were proportional, glucose utilization (percentage glucose uptake oxidized) remained similar in both patient groups. Furthermore, the hyperinsulinemic clamp lowered the plasma amino acid concentrations in the control patients while rHGH-treated patients had no significant alterations. In conclusion, exogenous growth hormone therapy induces an insulin resistance in burn patients. Furthermore, since the glucose utilization did not change, it is likely that the mechanism of insulin resistance is due to a deficiency in glucose transport.",
author = "Dennis Gore and Darcy Honeycutt and Farook Jahoor and Tom Rutan and Wolfe, {Robert R.} and David Herndon",
year = "1991",
doi = "10.1016/0022-4804(91)90175-L",
language = "English (US)",
volume = "51",
pages = "518--523",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of exogenous growth hormone on glucose utilization in burn patients

AU - Gore, Dennis

AU - Honeycutt, Darcy

AU - Jahoor, Farook

AU - Rutan, Tom

AU - Wolfe, Robert R.

AU - Herndon, David

PY - 1991

Y1 - 1991

N2 - The treatment of burn patients with recombinantly derived human growth hormone (rHGH) appears effective in counteracting protein catabolism. However, exogenous growth hormone is frequently associated with hyperglycemia, an aspect which may limit its usefulness. Therefore, to assess the affect of rHGH on glucose utilization, 13 severely burned patients (65% ± 4 TBSA burn; mean ± SEM) began receiving on admission either placebo or rHGH (0.2 mg/kg.d) in a double-blind randomized fashion. While hypermetabolic (percentage REE/predicted REE 1.41 ± 0.11) fasting oxygen consumption and CO2 production were measured using indirect calorimetry prior to and then during a hyperinsulinemic euglycemic clamp. This experiment demonstrated that rHGH significantly reduced glucose uptake and inhibited glucose oxidation compared to the placebo patients. Since the decreases in glucose oxidation and uptake were proportional, glucose utilization (percentage glucose uptake oxidized) remained similar in both patient groups. Furthermore, the hyperinsulinemic clamp lowered the plasma amino acid concentrations in the control patients while rHGH-treated patients had no significant alterations. In conclusion, exogenous growth hormone therapy induces an insulin resistance in burn patients. Furthermore, since the glucose utilization did not change, it is likely that the mechanism of insulin resistance is due to a deficiency in glucose transport.

AB - The treatment of burn patients with recombinantly derived human growth hormone (rHGH) appears effective in counteracting protein catabolism. However, exogenous growth hormone is frequently associated with hyperglycemia, an aspect which may limit its usefulness. Therefore, to assess the affect of rHGH on glucose utilization, 13 severely burned patients (65% ± 4 TBSA burn; mean ± SEM) began receiving on admission either placebo or rHGH (0.2 mg/kg.d) in a double-blind randomized fashion. While hypermetabolic (percentage REE/predicted REE 1.41 ± 0.11) fasting oxygen consumption and CO2 production were measured using indirect calorimetry prior to and then during a hyperinsulinemic euglycemic clamp. This experiment demonstrated that rHGH significantly reduced glucose uptake and inhibited glucose oxidation compared to the placebo patients. Since the decreases in glucose oxidation and uptake were proportional, glucose utilization (percentage glucose uptake oxidized) remained similar in both patient groups. Furthermore, the hyperinsulinemic clamp lowered the plasma amino acid concentrations in the control patients while rHGH-treated patients had no significant alterations. In conclusion, exogenous growth hormone therapy induces an insulin resistance in burn patients. Furthermore, since the glucose utilization did not change, it is likely that the mechanism of insulin resistance is due to a deficiency in glucose transport.

UR - http://www.scopus.com/inward/record.url?scp=0026335308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026335308&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(91)90175-L

DO - 10.1016/0022-4804(91)90175-L

M3 - Article

VL - 51

SP - 518

EP - 523

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 6

ER -